Source comparison
Thymosin Alpha-1 Applications: Acute vs Chronic Timeline Comparison
Acute viral infection (influenza, COVID-19) IFN-γ elevation, symptom duration reduction 7–14 days TLR activation → dendritic cell maturation → NK cell cytotoxicity Adjunctive use only. Not a replacement for antivirals. Reduces symptom severity by 20–30% in con
This comparison does not assign a generated winner or score.
- Acute viral infection (influenza, COVID-19)
- IFN-γ elevation, symptom duration reduction
- 7–14 days
- TLR activation → dendritic cell maturation → NK cell cytotoxicity
- Adjunctive use only. Not a replacement for antivirals. Reduces symptom severity by 20–30% in controlled trials.
- Chronic hepatitis B
- HBV DNA log reduction ≥1.5
- 8–12 weeks
- Sustained Th1 shift → CTL (cytotoxic T-lymphocyte) activation → viral clearance
- Responder rate 40–50%. Non-responders show <0.5 log reduction even at 24 weeks.
- Autoimmune conditions (lupus, RA)
- Flare frequency reduction, IL-10 upregulation
- 10–14 weeks
- Treg expansion → IL-10 secretion → suppression of autoreactive T-cells
- Best results as adjunct to DMARDs, not monotherapy. Flare reduction averages 35–45%.
- Cancer immunotherapy adjunct
- Tumor-infiltrating lymphocyte (TIL) density
- 6–10 weeks
- Dendritic cell antigen presentation → CD8+ T-cell priming
- Used in combination with checkpoint inhibitors. Monotherapy effect minimal.
- Post-viral fatigue syndromes
- Fatigue severity score reduction
- 12–16 weeks
- Mitochondrial function improvement via reduced oxidative stress
- Weakest evidence base. Mechanism poorly understood. Responder identification unclear.